New published article: Menghoum et al., 2024

Congratulations to Dr. Menghoum and colleagues on the publication of their paper on the role of carbohydrate antigen 125 (CA 125) as a marker in heart failure (HF) in the journal ESC Heart Failure. We are delighted to have contributed to the success of this article!

𝐇𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐩𝐫𝐞𝐬𝐞𝐫𝐯𝐞𝐝 𝐞𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐫𝐚𝐜𝐭𝐢𝐨𝐧 (HFPEF) accounts for 50% of all HFs. It is associated with high morbidity and mortality, and numerous comorbidities. Diagnosis is difficult, and therapeutic strategies have had limited impact on prognosis to this day. Identifying 𝐚𝐭 𝐫𝐢𝐬𝐤 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 is essential for optimal management. Thus, the authors 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐨𝐧 𝐂𝐀 𝟏𝟐𝟓, as previous studies have shown that elevated levels are 𝐚𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐜𝐨𝐧𝐠𝐞𝐬𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐩𝐨𝐨𝐫 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐢𝐬 in both HF and HFPEF.

A total of 139 patients with HFPEF and 25 control subjects were included in the study. CA 125 levels were 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭𝐥𝐲 𝐡𝐢𝐠𝐡𝐞𝐫 in patients with HFPEF compared with control subjects, and correlated positively with 𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐨𝐟 𝐜𝐨𝐧𝐠𝐞𝐬𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐟𝐢𝐛𝐫𝐨𝐬𝐢𝐬. A CA 125 level ≥35U/mL was a 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐨𝐫 of the composite endpoint (all-cause mortality or first hospitalization for HF) in HFPEF patients.

The advantages of CA 125 are its 𝐥𝐨𝐰 𝐢𝐧𝐭𝐞𝐫-𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥 𝐯𝐚𝐫𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 compared with other markers such as natriuretic peptides, as well as its 𝐥𝐨𝐰 𝐜𝐨𝐬𝐭 and feasibility in 𝐫𝐨𝐮𝐭𝐢𝐧𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐞𝐬. These data suggest that this marker could be used to identify patients with HFPEF requiring 𝐜𝐥𝐨𝐬𝐞𝐫 𝐟𝐨𝐥𝐥𝐨𝐰-𝐮𝐩. The article is already available on the journal's website! 𝐃𝐎𝐈: 𝟏𝟎.𝟏𝟎𝟎𝟐/𝐞𝐡𝐟𝟐.𝟏𝟒𝟔𝟗𝟗